

KASIC NEWSLETTER

Issue Six, Volume Two



Pictured Top: Bardstown, KY
Attribution to bardstownmainstreet.com

New Drugs for Bad Bugs

Cefepime-Enmetazobactam



This is an intravenous β -lactam/ β -lactamase inhibitor antibiotic active against Enterobacterales (e.g. *E. coli*) and *Pseudomonas aeruginosa*. Importantly, it is active against [ESBL producing organisms](#).

A [phase 3 trial](#) established efficacy of this novel drug compared with piperacillin-tazobactam for complicated UTIs and acute pyelonephritis. Although the study found superiority with cefepime-enmetazobactam, it should be noted that the piperacillin-tazobactam group included isolates with high MICs that would be considered resistant by current CLSI standards. This likely biased this group toward more treatment failures in the piperacillin-tazobactam group.

Cefepime-enmetazobactam is a new option for patients with resistant, difficult to treat isolates which are not susceptible to preferred therapies.

Cefepime-Taniborbactam

This novel antibiotic also recently established clinical efficacy in a [phase 3 trial](#). However, at this time it is **not FDA approved** pending manufacturing issues identified during the approval process. Stay tuned!

Vaccine Updates

The Centers for Disease Control and Prevention (CDC) has released the updated vaccine schedule for adults, children, and adolescents. The CDC provides recommendations based on age and certain risk factors. A notable change includes the updated respiratory syncytial virus (RSV) vaccine for pregnant women during RSV season and for individuals 60 years old and greater. Additionally, the most updated recommendations for COVID-19 and pneumococcal vaccines are included to guide institutions that may be implementing pneumococcal vaccine recommendations with the updated PCV15 or PCV20 vaccine.

[Click here to see updated CDC vaccine schedules](#)

Contact KASIC today for assistance with resistant organisms at your facility!



KASIC Cases

Each week, a fictional case describing a common antimicrobial stewardship opportunity is posted on X (formerly Twitter) and LinkedIn. Participants are encouraged to answer the poll first and then review the best answer along with an explanation.

Ready to test your antimicrobial stewardship knowledge? Try out the latest case:

A patient is admitted for a diabetic foot infection with concern for osteomyelitis. He is not septic and awaiting surgical plans. What is the BEST antibiotic plan?

- A. Hold antibiotics
- B. Start vancomycin
- C. Start cefepime
- A. Start vancomycin and cefepime

[Click here for the BEST answer](#)

[Read more cases here](#)

[Follow KASIC on Twitter & LinkedIn](#)

Latest Clinical Education Pearls: Click to Read!

[*Prescription Planning with Procalcitonin for Pneumonia*](#)

[*Antimicrobial Stewardship Opportunity: Duplicate Anaerobic Coverage*](#)

[*Beta-lactamases: Focus on Carbapenemases*](#)

[*Enhancing Itraconazole Absorption*](#)

Norton Infectious Diseases Institute Grand Rounds Educational Series

[*Cool Molecular Tests – For Better and Worse*](#)

[*Matrix-Assisted Laser Desorption Ionization - MALDI*](#)

[*Interpreting SIR and SUR*](#)

[Click here for Grand Rounds Information](#)